Table 2.
Patients and disease characteristics.
| IBD (n=200) | CD (n=157) | UC (n=41) | p-value | |
|---|---|---|---|---|
| Patients' proportion | 100% | 78.50% | 20.50% | |
|
| ||||
| Mean age (years) | 48.4 ± 13.9 | 48.5 ± 14.3 | 48.7 ± 12.5 | 0.92 |
|
| ||||
| Mean length of disease (years) | 17.3 ± 11.6 | 19.1 ± 12.0 | 11.3 ± 7.3 | <0.01 |
|
| ||||
| Mean length of follow up (years) | 4.3 ± 1.8 | 4.4 ± 1.9 | 5.2 ± 5.9 | 0.86 |
|
| ||||
| Men, n (%) | 77 (38.5%) | 57 (36.3%) | 17 (41.5%) | 0.54 |
|
| ||||
| ≥1 IBD-related intestinal resection, n (%) | 69 (34.5%) | 65 (41.4%) | 3 (7.3%) | <0.01 |
|
| ||||
| Treatment, n (%) | ||||
|
| ||||
| 5-Aminosalicylate, n (%) | 57 (28.5%) | 27 (17.3%) | 29 (70.7%) | <0.01 |
|
| ||||
| Immunomodulator, n (%) | 59 (29.5%) | 52 (33.1%) | 7 (17.1%) | 0.05 |
|
| ||||
| Biologic agent, n (%) | 76 (38.0%) | 70 (44.6%) | 6 (14.6%) | <0.01 |
|
| ||||
| Chronic prednisone, n (%) | 3 (1.5%) | 3 (1.9%) | 0 (0%) | 0.86 |
|
| ||||
| Corticosteroids in the last year, n (%) | 25 (12.5%) | 22 (14.0%) | 3 (7.3%) | 0.25 |
|
| ||||
| Access to the provincial register, n (%) | 163 (81.5%) | 129 (82.2%) | 33 (80.4%) | 0.80 |
|
| ||||
| Mean CED (mSv) | 23.1 ± 45.2 | 27.5 ± 49.5 | 6.8 ± 14.8 | <0.01 |
|
| ||||
| Exposed to a CED ≥100 mSv, n (%) | 6 (3%) | 6 (3.8%) | 0 (0%) | 0.20 |
CD, Crohn's disease. CED, cumulative effective dose. IBD, intestinal bowel disease. mSv, millisievert. UC, ulcerative colitis.
∗p value between CD and UC.